Cargando…

Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides

Pancreatic neuroendocrine tumours (pNETs) secreting proglucagon are associated with phenotypic heterogeneity. Here, we describe two patients with pNETs and varied clinical phenotypes due to differential processing and secretion of proglucagon-derived peptides (PGDPs). Case 1, a 57-year-old woman pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Challis, Benjamin G, Albrechtsen, Nicolai J Wewer, Bansiya, Vishakha, Burling, Keith, Barker, Peter, Hartmann, Bolette, Gribble, Fiona, O'Rahilly, Stephen, Holst, Jens J, Simpson, Helen L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685488/
https://www.ncbi.nlm.nih.gov/pubmed/26693280
http://dx.doi.org/10.1530/EDM-15-0105
_version_ 1782406325494349824
author Challis, Benjamin G
Albrechtsen, Nicolai J Wewer
Bansiya, Vishakha
Burling, Keith
Barker, Peter
Hartmann, Bolette
Gribble, Fiona
O'Rahilly, Stephen
Holst, Jens J
Simpson, Helen L
author_facet Challis, Benjamin G
Albrechtsen, Nicolai J Wewer
Bansiya, Vishakha
Burling, Keith
Barker, Peter
Hartmann, Bolette
Gribble, Fiona
O'Rahilly, Stephen
Holst, Jens J
Simpson, Helen L
author_sort Challis, Benjamin G
collection PubMed
description Pancreatic neuroendocrine tumours (pNETs) secreting proglucagon are associated with phenotypic heterogeneity. Here, we describe two patients with pNETs and varied clinical phenotypes due to differential processing and secretion of proglucagon-derived peptides (PGDPs). Case 1, a 57-year-old woman presented with necrolytic migratory erythema, anorexia, constipation and hyperinsulinaemic hypoglycaemia. She was found to have a grade 1 pNET, small bowel mucosal thickening and hyperglucagonaemia. Somatostatin analogue (SSA) therapy improved appetite, abolished hypoglycaemia and improved the rash. Case 2, a 48-year-old male presented with diabetes mellitus, diarrhoea, weight loss, nausea, vomiting and perineal rash due to a grade 1 metastatic pNET and hyperglucagonaemia. In both cases, plasma levels of all measured PGDPs were elevated and attenuated following SSA therapy. In case 1, there was increased production of intact glucagon-like peptide 1 (GLP-1) and GLP-2, similar to that of the enteroendocrine L cell. In case 2, pancreatic glucagon was elevated due to a pancreatic α-cell-like proglucagon processing profile. In summary, we describe two patients with pNETs and heterogeneous clinical phenotypes due to differential processing and secretion of PGDPs. This is the first description of a patient with symptomatic hyperinsulinaemic hypoglycaemia and marked gastrointestinal dysfunction due to, in part, a proglucagon-expressing pNET. LEARNING POINTS: PGDPs exhibit a diverse range of biological activities including critical roles in glucose and amino acid metabolism, energy homeostasis and gastrointestinal physiology. The clinical manifestations of proglucagon-expressing tumours may exhibit marked phenotypic variation due to the biochemical heterogeneity of their secreted peptide repertoire. Specific and precise biochemical assessment of individuals with proglucagon-expressing tumours may provide opportunities for improved diagnosis and clinical management.
format Online
Article
Text
id pubmed-4685488
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-46854882015-12-21 Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides Challis, Benjamin G Albrechtsen, Nicolai J Wewer Bansiya, Vishakha Burling, Keith Barker, Peter Hartmann, Bolette Gribble, Fiona O'Rahilly, Stephen Holst, Jens J Simpson, Helen L Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy Pancreatic neuroendocrine tumours (pNETs) secreting proglucagon are associated with phenotypic heterogeneity. Here, we describe two patients with pNETs and varied clinical phenotypes due to differential processing and secretion of proglucagon-derived peptides (PGDPs). Case 1, a 57-year-old woman presented with necrolytic migratory erythema, anorexia, constipation and hyperinsulinaemic hypoglycaemia. She was found to have a grade 1 pNET, small bowel mucosal thickening and hyperglucagonaemia. Somatostatin analogue (SSA) therapy improved appetite, abolished hypoglycaemia and improved the rash. Case 2, a 48-year-old male presented with diabetes mellitus, diarrhoea, weight loss, nausea, vomiting and perineal rash due to a grade 1 metastatic pNET and hyperglucagonaemia. In both cases, plasma levels of all measured PGDPs were elevated and attenuated following SSA therapy. In case 1, there was increased production of intact glucagon-like peptide 1 (GLP-1) and GLP-2, similar to that of the enteroendocrine L cell. In case 2, pancreatic glucagon was elevated due to a pancreatic α-cell-like proglucagon processing profile. In summary, we describe two patients with pNETs and heterogeneous clinical phenotypes due to differential processing and secretion of PGDPs. This is the first description of a patient with symptomatic hyperinsulinaemic hypoglycaemia and marked gastrointestinal dysfunction due to, in part, a proglucagon-expressing pNET. LEARNING POINTS: PGDPs exhibit a diverse range of biological activities including critical roles in glucose and amino acid metabolism, energy homeostasis and gastrointestinal physiology. The clinical manifestations of proglucagon-expressing tumours may exhibit marked phenotypic variation due to the biochemical heterogeneity of their secreted peptide repertoire. Specific and precise biochemical assessment of individuals with proglucagon-expressing tumours may provide opportunities for improved diagnosis and clinical management. Bioscientifica Ltd 2015-12-01 2015 /pmc/articles/PMC4685488/ /pubmed/26693280 http://dx.doi.org/10.1530/EDM-15-0105 Text en © 2015 The authors This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) .
spellingShingle Insight into Disease Pathogenesis or Mechanism of Therapy
Challis, Benjamin G
Albrechtsen, Nicolai J Wewer
Bansiya, Vishakha
Burling, Keith
Barker, Peter
Hartmann, Bolette
Gribble, Fiona
O'Rahilly, Stephen
Holst, Jens J
Simpson, Helen L
Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
title Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
title_full Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
title_fullStr Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
title_full_unstemmed Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
title_short Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
title_sort heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
topic Insight into Disease Pathogenesis or Mechanism of Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685488/
https://www.ncbi.nlm.nih.gov/pubmed/26693280
http://dx.doi.org/10.1530/EDM-15-0105
work_keys_str_mv AT challisbenjaming heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT albrechtsennicolaijwewer heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT bansiyavishakha heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT burlingkeith heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT barkerpeter heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT hartmannbolette heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT gribblefiona heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT orahillystephen heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT holstjensj heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides
AT simpsonhelenl heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides